Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Inventory (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Change in Inventory for 7 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 638.87% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.8 million through Dec 2025, down 200.33% year-over-year, with the annual reading at -$1.8 million for FY2025, 200.33% down from the prior year.
  • Change in Inventory hit -$1.5 million in Q4 2025 for Harmony Biosciences Holdings, down from $782000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $1.3 million in Q3 2024 to a low of -$1.5 million in Q4 2025.
  • Historically, Change in Inventory has averaged $76700.0 across 5 years, with a median of $199000.0 in 2022.
  • Biggest five-year swings in Change in Inventory: surged 445.92% in 2024 and later plummeted 638.87% in 2025.
  • Year by year, Change in Inventory stood at -$373000.0 in 2021, then soared by 206.43% to $397000.0 in 2022, then crashed by 30.48% to $276000.0 in 2023, then increased by 2.54% to $283000.0 in 2024, then tumbled by 638.87% to -$1.5 million in 2025.
  • Business Quant data shows Change in Inventory for HRMY at -$1.5 million in Q4 2025, $782000.0 in Q3 2025, and -$284000.0 in Q2 2025.